Comparison of Paricalcystol and Calcitriol Treatment in terms of inflammation in Hemodialysis Patients

Öz

Abstract Objective: Chronic kidney disease is a multisystemic, inflammatory disease. Although atherosclerotic heart disease is the most important cause of mortality in hemodialysis patients, malnutrition and inflammation constitute an additional risk factor in this patient group. In this study, we aimed to investigate inflammation among hemodialysis patients using paricalcitol and calcitriol. Material-Method: This study was carried out retrospectively, cross-sectionally and descriptively. From the 241 hemodialysis patients; 30 patients were included in the paricalcitol group and 58 patients were included in the calcitriol group. Neutrophil lymphocyte ratio (NLO), high sensitivity C reactive protein (hs-CRP), important clinical and laboratory data were recorded. Pearson correlation test was applied to show the relationship between NLO and hs-CRP. Results: 59 of the patients were male and 29 were female. The mean age was 62.9 ± 14.8 years in the paricalcitol group and 59 ± 13.9 years in the calcitriol group (p: 0.20). The concentration of NLO and hs-CRP was similar in the paricalcitol and calcitriol group (p: 0.42, p: 0.51, respectively). There was no significant difference between groups in terms of albumin and ferritin levels (p: 0.55, p: 0.68, respectively). A positive correlation was found between NLO and hs-CRP (r: 0.471, p: 0.001). Conclusion: Although hemodialysis patients included in the study had a positive relationship between NLO, which can be obtained easily and cheaply from complete blood count, and hs-CRP, there was no difference in terms of inflammation between the groups receiving paricalcitol and calcitriol treatment. Considering our study, prospective studies involving more patients are needed.

Anahtar Kelimeler

• Hemodialysis
• inflammation
• neutrophil/lymphocyte ratio
• paricalcitol
• calcitriol

Hemodiyaliz Hastalarında Parikalsitol ve Kalsitriol Tedavisinin İnflamasyon Açısından Karşılaştırılması

Öz

Özet Amaç: Kronik böbrek hastalığı multisistemik, inflamatuar bir hastalıktır. Hemodiyaliz hastalarında aterosklerotik kalp hastalığı mortalitenin en önemli nedeni olmasına rağmen malnutrisyon ve inflamasyon bu hasta grubunda ek risk faktörü oluşturur. Bu çalışmada parikalsitol ile kalsitriol kullanan hemodiyaliz hastaları arasında inflamasyonun incelenmesi amaçlandı. Materyal-Metod: Bu çalışma retrospektif, kesitsel ve tanımlayıcı olarak gerçekleştirildi. Çalışmaya hemodiyaliz tedavisi alan 241 hastadan parikalsitol grubuna 30 ve kalsitriol grubuna 58 hasta olacak şekilde dahil edildi. Nötrofil lenfosit oranı (NLO), yüksek duyarlıklı C reaktif protein (hs-CRP) ve önemli klinik ve laboratuvar veriler kaydedildi. NLO ve hs-CRP arasındaki ilişkiyi göstermek için pearson korelasyon testi uygulandı. Bulgular: Hastaların 59’u erkek 29’u kadınlardan oluşmaktaydı. Yaş ortalaması parikalsitol grubunda 62.9±14.8 kalsitriol grubunda 59±13.9 yıldı (p:0.20). NLO ve hs-CRP konsantrasyonu parikalsitol ve kalsitriol grubunda benzerdi (sırasıyla p:0.42, p:0.51). Gruplar arasında albümin ve ferritin düzeyleri açısından anlamlı fark saptanmadı (sırasıyla p:0.55, p:0.68). NLO ile hs-CRP arasında pozitif bir korelasyon saptandı (r:0.471, p:0.001). Sonuç: Çalışmaya dahil edilen hemodiyaliz hastalarında, kolay ve ucuz olarak tam kan sayımından elde edilebilen NLO ile hs-CRP arasında pozitif bir ilişki saptanmasına rağmen parikalsitol ve kalsitriol tedavisi alan gruplar arasında inflamasyon açısından bir fark saptanmadı. Bizim yaptığımız çalışmaya dayanarak daha yüksek hasta popülasyonunun dahil edildiği prospektif araştırmalara ihtiyaç vardır.

Anahtar Kelimeler

• Hemodiyaliz
• inflamasyon
• nötrofil/lenfosit oranı
• parikalsitol
• kalsitriol

Kaynakça

1. 1. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-infammatory cytokines. Nephrol Dial Transplant 2001;16(6):1189–1197.
2. 2. Stenvinkel P. Infammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002;17(Suppl 8):33–38.
3. 3. Saeed Z, Ahmad AM, Shakoor A, Ghafoor F, Kanwal S: Depression in patients on hemodialysis and their caregivers. Saudi J Kidney Dis Transpl 2012;23(5):946-952.
4. 4. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001;38:1343–1350.
5. 5. Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patientswith end-stage renal disease: a century-old phenomenon. Kidney Int 2002;82(Suppl):73–80.
6. 6. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE. Coresh J, et al. Changes in serum calcium, phosphate and PTH and the risk of death in incident dialysis patients:A longitudinal study. Kidney Int. 2006;70(2): 351–357.
7. 7. Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc 2010;85(8):752-758.
8. 8. Pilz S, Tomaschitz A, Drechsler C, de Boer RA. Vitamin D deficiency and heart disease. Kidney International Supplements 2011;1:111-115.

9. 9. Andress DL. Intravenous versus oral vitamin D therapy in dialysis patients. What is the question? Am J Kidney Dis 2001; 38: 41–44.
10. 10. Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, et al. The mechanism for the disparate actions of calcitriol and 22–oxacalcitriol in the intestine. Endocrinology 1993; 133: 1158–64. 83.
11. 11. Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, et al. A new analog of calcitriol, 19– nor–1,25–(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852–860.
12. 12. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19–nor–1–alpha–25–dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427–1432.
13. 13. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483–1490.
14. 14. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004;13(1):93–99)
15. 15. Bikle DD, Oda Y, Xie Z. Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation. J Steroid Biochem Mol Biol 2004;89-90:355-360.
16. 16. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 2013(3);1.
17. 17. Vandana M, Xuelei W, Tom G, Gerald JB, John WK, Santica MM, et al. Relationship Between C-Reactive Protein, Albumin, and Cardiovascular Disease in Patients With Chronic Kidney Disease. American Journal of Kidney Diseases, Vol 42, No 1 (July), 2003: pp 44-52.
18. 18. An X, Mao HP, Wei X, Chen JH, Yang X, Li ZB, et al. Elevated neutrophil to lymphocyte ratio predicts overall and cardiovascular mortality in maintenance peritoneal dialysis patients. Int Urol Nephrol. 2012;44:1521–1528.
19. 19. Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail. 2012;34: 155–159.
20. 20. Sen BB, Rifaioglu EN, Ekiz O, Inan MU, Sen T, Sen N. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol 2014;33: 223-227.
21. 21. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999 May; 55(5):1899-911.
22. 22. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardio vascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–352.
23. 23. Stevinkel P. The role of inflammation in the anaemia of end stage renal disease. Nephrol Dial Transplant 2001; 13 (Suppl): 28–36.
24. 24. Yudan W, Jing L, Fan Y, Xiujiang L, Yue H, Ronghua L, et al. Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease. Exp Ther Med. 2016 Aug; 12(2): 1206–1212.
25. 25. Eleonora R, Massimo S, Dario B, Ivana C, Silvia M, Michele A, et al. Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial. PLoS One. 2015; 10(3): e0118174. Published online 2015 Mar 17. doi: 10.1371/journal.pone.0118174
26. 26. Solak Y, Yilmaz MI, Sonmez A, Saglam M, Cakir E, Unal HU, et al. Neutrophil to lymphocyte ratio independently predicts cardiovas cular events in patients with chronic kidney disease. Clin Exp Nephrol. 2013;17(4):532–40.
27. 27. Senol T, Cavit C, Sedat Y, Mine Sebnem K. Does neutrophil to lymphocyte ratio demonstrate deterioration in renal function? Ren Fail. 2018; 40(1): 209–212.
28. 28. Okyay GU, Inal S, Onec K, Er RE, Paşaoğlu O, Paşaoğlu H, et al. Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Ren Fail. 2013;35:29–36.
29. 29. Neuen BL, Leather N, Greenwood AM, Gunnarsson R, Cho Y, Mantha ML, et al. Neutrophil-lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients. Ren Fail. 2016;38:70–76.
30. 30. Han L, Xiangxue L, Ruifang X, Shixiang W. High Neutrophil-to-Lymphocyte Ratio Predicts Cardiovascular Mortality in Chronic Hemodialysis Patients. Mediators Inflamm. 2017; 2017: 9327136. Published online 2017 Feb 21. doi: 10.1155/2017/9327136
31. 31. Bal ÖK. Kronik renal yetmezlikli hastalarda parikalsitol ve kalsitriol tedavisinin fetuin A ve inflamasyon belirteçleri üzerine etkilerinin karşılaştırılması 2009 - acikerisim.uludag.edu.tr
32. 32. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM, et al: Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int 1996,16:158-162.
33. 33. Ema JJ, Abdul H, Abdul G, Loo CY, Rizna C, Rozita M, et al. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol (2014) 18:507–514 DOI 10.1007/s10157-013-0844-2